Serial Circulating Tumour Cell Monitoring During Androgen Deprivation and Docetaxel Therapies Identifies Poor Prognostic Metastatic Prostate Cancer
Cancers · 17.11.2026 · 18 (22) · 3671
DOI: 10.3390/cancers18223671 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 17.11.2026. Verfasst von Caitlin R. Davies und 21 weiteren Autor:innen. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Orchid Cancer Appeal, Cancer Research UK.
Abstract (Originalsprache)
Background/Objectives: Adding docetaxel to androgen deprivation therapy (ADT) prolongs survival in metastatic prostate cancer, but not all patients benefit, and no early biomarker identifies individuals with resistant disease. We assessed whether serial circulating tumour cell (CTC) sampling adds prognostic information beyond a pre-treatment sample.
Methods
CTCs were enriched by size and deformability (Parsortix®) and phenotyped as epithelial (CK+/VIM−/CD45−), mesenchymal (CK−/VIM+/CD45−), or EMTing (CK+/VIM+/CD45−) at four time points in 61 patients treated with ADT and docetaxel (43 hormone-sensitive; 18 resistant, exploratory).
Results
With longer follow-up, our previously reported baseline CTC predictors remained associated with overall survival (OS). In hormone-sensitive patients, baseline ≥ 6 total (HR 3.21, p = 0.007) and epithelial CTCs (p = 0.017) were associated with shorter OS. Across baseline, early, and late treatment, the OS hazard ratio for epithelial CTCs fell (2.59, 2.29, 2.11), yet for ≥3 mesenchymal CTCs rose (1.99, 2.99, 4.08). No single time point result survived false-discovery-rate correction. During early treatment, radiographic responders had fewer mesenchymal CTCs than non-responders (median 0 vs. 2.5, p = 0.032), whereas PSA did not differ (p = 0.642). Persistence of ≥3 mesenchymal CTCs from baseline to late treatment identified the poorest outcome (n = 3; median OS 17.3 months vs. not reached) and survived false-discovery-rate correction (q = 0.019). Late treatment mesenchymal CTCs added value to baseline PSA (p = 0.024) and ALP (p = 0.019) and added potential value to the best baseline marker (≥6 CTCs, p = 0.125), identifying some high-risk patients with baseline < 6 CTCs.
Conclusions
Early on-treatment CTC samples may help predict response, while late treatment mesenchymal CTCs may add to baseline clinical markers. These hypothesis-generating findings require validation in a larger prospective cohort.
Förderung
- Medical Research Council
- Orchid Cancer Appeal
- Cancer Research UK
- Chinese Scholarship Council
Zitieren
APA
Davies, C. R., Burke, E., Guo, T., Stankiewicz, E., Xu, L., Mao, X., Scandura, G., Rajan, P., McCarley, S., Tipples, K., Alifrangis, C., Wimalasingham, A. G., Galazi, M., Crusz, S. M., Powles, T., Grey, A., Kudahetti, S., Shaw, G., Berney, D., …, & Lu, Y. (2026). Serial Circulating Tumour Cell Monitoring During Androgen Deprivation and Docetaxel Therapies Identifies Poor Prognostic Metastatic Prostate Cancer. Cancers, 18(22), 3671. https://doi.org/10.3390/cancers18223671
Vancouver
Davies CR, Burke E, Guo T, Stankiewicz E, Xu L, Mao X, et al. Serial Circulating Tumour Cell Monitoring During Androgen Deprivation and Docetaxel Therapies Identifies Poor Prognostic Metastatic Prostate Cancer. Cancers. 2026;18(22):3671. doi:10.3390/cancers18223671
BibTeX
@article{Davies2026,
author = {Davies, Caitlin R. and Burke, Edwina and Guo, Tianyu and Stankiewicz, Elzbieta and Xu, Lei and Mao, Xueying and Scandura, Glenda and Rajan, Prabhakar and McCarley, Sarah and Tipples, Karen and Alifrangis, Constantine and Wimalasingham, Akhila G. and Galazi, Myria and Crusz, Shanthini M. and Powles, Thomas and Grey, Alistair and Kudahetti, Sakunthala and Shaw, Greg and Berney, Daniel and Shamash, Jonathan and Blyuss, Oleg and Lu, Yong-Jie},
title = {Serial Circulating Tumour Cell Monitoring During Androgen Deprivation and Docetaxel Therapies Identifies Poor Prognostic Metastatic Prostate Cancer},
journal = {Cancers},
year = {2026},
volume = {18},
number = {22},
pages = {3671},
doi = {10.3390/cancers18223671}
}
EUVIMED